2026 Poster Presentations

CAST YOUR VOTE FOR BEST OF SHOW POSTER AWARD
https://www.discoveryontarget.com/best-of-show-poster-award
Voting Opens Tuesday, September 29 at 3:50pm

ACADEMIC POSTER PAVILION

A01: Next-Generation Immunosuppressive ADCs: Targeted Delivery of Glucocorticoids to Activated Immune Cells for Chronic Inflammation, Presented by Nathan T., Binghamton University, State University of New York

A02: The Influence of Ligands on AlphaFold3 Prediction of Cryptic Pockets, Presented by Felix T., Boston University

A03: Structure-Based Repurposing of FDA-Approved Drugs Identifies Candidate Cereblon Modulators, Presented by Vivek S., Case Western Reserve University

A04: Driving Radical Pharmaceutical Innovation in Brazil: The Integrated Drug Discovery Platform of LNBio/CNPEM, Presented by Alisson C., CNPEM - Brazilian Center for Research in Energy and Materials

A05: Antibodies Generated by Conformational Subtraction Differentiate Between Soluble and Membrane Bound Antigen, Presented by John W., EFS - French Blood Establishment, in collaboration with Mab Designs Ltd.

A06: Target Deconvolution Using a 29,000-Human-Protein Array and AlphaScreen, Presented by Hiroyuki T., Ehime University

A07: Development of Antiviral Drug via High-Throughput Screening and Phenotypic Image-Based AI Predictive Models, Presented by BoRa L., Institut Pasteur Korea

A08: TXNIP Deficiency Exacerbates Experimental Colitis in Mice, Presented by Jong Soon K., Korea Research Institute of Bioscience and Biotechnology

A09: Pharmacological Targeting of Sirtuin 7(SIRT7) with a Novel Small-Molecule Inhibitor Suppresses Hepatocellular Carcinoma Growth, Presented by Songyi B., Korea Research Institute of Chemical Technology

A10: Cell-Free Synthesis of Human Channel Proteins Enables Antibody Generation Against Challenging Channel Proteins, Presented by Wei Z., Kyoto University

A11: Small-Molecule Inhibitors of Nuclear Kinase ULK3 as a Strategy to Target Shared Epithelial–Stromal Regulatory Nodes for Skin Tumor Development and Field Cancerization, Presented by Sandro G., Massachusetts General Hospital

A12: Integrating Physics-Based Modeling and AI for Ligand Optimization, Presented by Marina G., Moffitt Cancer Center & Research Institute

A13: Structure-Based De Novo Peptide Design to Block Hemoglobin S Polymerization, Presented by Mamadou S., National Institutes of Health, National Institute of Allergy and Infectious Diseases

A14: AI-Assisted Design of mTOR Inhibitors for Autism Spectrum Disorder, Presented by Jane H., Princeton High School

A15: A Proteome-Wide HuProt™ Microarray-Based Approach for Natural Product Target Identification, Presented by Grace VC., Puerto Rico Science, Technology & Research Trust

A16: Discovering New Mechanism of Action to Drive New Therapeutic Development in T Cell-Mediated Diseases, Presented by David O., University College Dublin

A17: Molecular Dynamics Simulations of Metabolite and Peptide Fibrils, Presented by Pavel R., University of Illinois at Chicago

A18: Single Domain Antibodies Targeting the Third Intracellular Loop Are Receptor Subtype-Selective Allosteric Modulators, Presented by Fredrik S., University of Minnesota

A19: Development of CORTACs as a Small Molecule Strategy to Enhance Degrader Specificity, Presented by Davis C., Yale University

A20: Integrative Chemical Genetics Platform Identifies Condensate Modulators Linked to Neurological Disorders, Presented by Dylan P., Yale University

COMMERCIAL POSTERS

C001: Unlocking the Full Potential of Antibody-Based Conjugates with AJICAP® Site-Specific Chemical Conjugation and Linker Technologies, Presented by Masahito K., Ajinomoto Bio-Pharma Services

C002: De-Risk Early Discovery. Expand Your IP Protection: Find Active Scaffolds via Exhaustive 2D & 3D Analogue Search in Commercial Trillion-Scale Spaces, Presented by Christian L., Alipheron AG

C003: Establishment of Spectral Shift Binder HTS Platform, Presented by Matthew C., Amgen, Inc.

C004: Application of NanoBRET Technology for Hit Prioritization in a Protein-Protein Interaction Drug Discovery Program, Presented by Siying Z., Amgen, Inc.

C005: One Chemistry Platform, Multiple Modalities: Accelerating Drug Discovery Through Advanced Synthesis Technologies, Presented by Tarunkanti P., Aragen Life Sciences

C006: Selective Sensor Peptide Substrates Enable Continuous Kinetic Quantitation of Kinase Activity in Unfractionated Cell Lysates, Presented by Erik S., AssayQuant Technologies, Inc.

C007: Discovery of ASTX295 - A Bone-Marrow Sparing MDM2 Antagonist: From Concept to Clinic, Presented by Louise W., Astex Pharmaceuticals

C008: PharmMaster: From Target Insight to Molecular Design, Presented by Tianming Q., Atombeat, a DP Technology Company

C009: Standardized Computational Services, Presented by Jiayue W., Atombeat, a DP Technology Company

C010: Amplifying the Therapeutic Potential of Rabbit-Derived Antibodies by an Advanced High-Throughput, Multi-Parametric Humanization Approach for Single-Step Engineering, Presented by Diana C., AVS Bio

C011: Boosting Diversity-Focused Lead Antibody Generation by In Silico-Guided Rare Hit Magnification and Epitope-Driven Affinity Finetuning, Presented by Ilse R., AVS Bio

C012: Structural Characterization of Protein Degraders via Cryo-EM and Crystallography, Presented by Tao W., Biortus Discovery, a Pharmaron Company

C013: Surface Plasmon Resonance Microscopy Reveals Distinct Binding Kinetics of Small Molecules, Peptides, and Antibodies to GLP-1R on Whole Cells, Presented by Akemi U., Biosensing Instrument

C014: Evaluating STAT6-Targeting Degraders Using Complementary Biochemical and Cell-Based Assays, Presented by Pavel S., BPS Bioscience, Inc.

C015: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Nicholas A., Carterra, Inc.

C016: High-Throughput SPR Screening and Kinetic Characterization Using Carterra Vega™ with AI Binding Prediction Comparison, Presented by Perry R., Carterra, Inc.

C017: Validation and Characterization of Anti-Citrulline Antibodies and Citrullinated Proteins, Presented by Zahra AN.., Cayman Chemical Company

C018: The Cell Surface Is the Epitope: Native-Context Discovery for Difficult Membrane Targets, Presented by Mette S., Cell Origins

C019: Assessing Cellular Target Engagement with MICRO-TAG®: ARID1B as an “Undruggable" Case Study, Presented by Elmar N., CellarisBio

C020: Micro-Tag Cell Target Engagement Redefines GPCR Drug Discovery with Functional Relevance, Presented by Elmar N., CellarisBio

C021: Toward Canonical HELM Representations for Sequence-Level Peptide Registration, Presented by Jan C., Certara

C022: Separating WEE1 from PLK1: Structure-Based Design of Selective WEE1 Inhibitors, Presented by Adam D., Concept Life Sciences

C023: Targeting NLRP3 Inflammasome Assembly: Discovery of Small-Molecule Inhibitors for Neurological and Inflammatory Diseases, Presented by Adam D., Concept Life Sciences

C024: Accelerating PROTAC Discovery Through a Direct-to-Biology Platform for Rapid BRD4 Degrader Identification, Presented by Will B., Concept Life Sciences

C025: Development of a NEK7–NLRP3 Screening Cascade to Identify Potent, Selective Inhibitors for Neurological and Dermatological Disorders, Presented by Ana-Mishel S., Concept Life Sciences

C026: First Agonist Antibody Against a GPCR in Preclinical Development: CFTX-2034 for Post-Bariatric Hypoglycemia, Presented by Michael D., Confo Therapeutics

C027: Unique Carrier-Free Immunization Can Generate Precision Antibodies Against High-Homology Short Peptide Targets, Presented by Bo L., Conigen Bioscience

C028: Monoclonal Antibodies Against a Panel of GPCRs Can Detect the Targets Expressed on the Surface of Live Cells by Flow Cytometry, Presented by Shixia W., Conigen Bioscience

C029: Accelerating Discovery of a METTL3 Inhibitor Through Efficient In Silico Design and Prioritization, Presented by Sylvie S., Cresset Biomolecular Discovery, Inc.

C030: From Copolymer Screening to Plug-and-Play Purification: Automated NativeMP™ Platforms for Membrane Proteins, Presented by Alice M., Cube Biotech

C031: iCLASS: Live-Cell Drug Discovery Platform for Small Molecule Therapeutics Against the “Hard-to-Drug” Protein Targets, Presented by Leland J., Dalriada Drug Discovery

C032: The Application of Synthetic Nanodisc (Syndisc™) and PeptiNanodisc™ Technology Platforms to Develop Therapeutic mAbs for Multi-Pass Transmembrane Protein Targets, Presented by Donghui M., DIMA

C033: Bringing Proteins Together: From Glue Identification to Mechanistic Understanding, Presented by Nicholas B., Domainex

C034: Building a Fragment-Based Drug Discovery Workflow for RNA Targets, Presented by Hayley F., Domainex

C035: PureDisc: Unlocking Membrane Proteins for Structural Biology and Biophysics Utilising Native Membrane Polymer Nanodiscs, Presented by Chris M., Domainex

C036: Unlocking the Unlockable: AS-MS for Swift Hit Identification Against Challenging Targets, Presented by Didier R., Edelris SAS

C037: Molecular Glue Discovery Through Novel Chemical Space and AS-MS Screening, Presented by Joseph Z., Edelris SAS

C038: Development of Novel Live Cell Based Screening Platform for GPCR-Stabilizing VHH Antibodies, Presented by Keehun K., Eli Lilly and Company

C039: Development of a Novel Platform for Directed Protein Evolution, Presented by Naduni P., Eli Lilly and Company

C040: Knowledge Graph Driven Insights and Drug Repurposing Opportunities for Neuroendocrine Prostate Cancer, Presented by Yogesh L., Elucidata Corporation

C041: Prime Editing to Create Near Pure Cysteine Mutant Cell Pools for Covalent Inhibitor Validation, Presented by Xiaofeng J., EMD Serono, a business of Merck KGaA

C042: Discovery of Highly Potent BRD4 Degraders in a Series of Phenyl Dihydrouracil (PDHU) Derivatives, Presented by Galyna D., Enamine

C043: Integrated High-Throughput Biochemical Binding and Cell-Based Targeted Protein Degradation Assay Platforms for STAT Degraders, Presented by Jean B., Eurofins Discovery

C044: A Binder-First Discovery Platform for Kinase Molecular Glues Based on High-Throughput Spectral Shift Assays, Presented by Maud S., Eurofins Discovery

C045: Accelerating Tyrosine Kinase Inhibitor Drug Discovery with Selective Late-Stage Functionalization Strategies, Presented by Zain Y., Eurofins Discovery

C046: Development of Antibody Conjugates via Site Directed Conjugation, Presented by Muctarr S., GBI Biomanufacturing

C047: Variance-Modeled DIA Improves Quantitative Precision Across Global and Phosphoproteomic Workflows, Presented by Jonathon O., Golgi

C048: From Design to Application: A CRBN Molecular Glue Library Featuring Diverse and Unique CRBN Binders, Presented by Zhenyu W., HitChem

C049: Hold-and-Kill: Validation Strategy of New RIPTAC Target Pairs, Presented by Tiejun B., ICE Bioscience

C050: Novel, Conformational Target Discovery in TKI-Resistant NSCLC, Presented by Hetal M., Immuto Scientific

C051: Developing 3D Cell Models for High-Throughput Antibody-Drug Conjugate Screening in Cancer, Presented by Morgan H., Inventia Life Science

C052: CDK4/6 PROTAC Degraders Design, Synthesis and Profiling, Presented by Srekanth R., Jubilant Biosys

C053: Enabling Structure Based Drug Discovery on Membrane Proteins, Presented by Michael H., leadXpro AG

C054: Envisia: Advancing Antibody Discovery with Function-Focused Profiling at the Single-Cell Level, Presented by Simon M., Lightcast Discovery Ltd.

C055: LiteFold-Infrastructure for Precision Therapeutics, Presented by Cory K., LiteFold, Inc.

C056: Pathway-Resolved Profiling Identifies Non-Canonical 5-HT7A/Gα15 Signaling by MSD-001 (5-MeO-MiPT), Presented by Robert S., Mindstate Design Labs, Inc.

C057: Peptide Macrocycles: A Global, Open-Access, In-Stock Resource for Challenging Drug Targets, Presented by Diana ZG. & Rolands C., Molport

C058: Accelerated Antibody Characterization - Sequence to SPR in 7 days, Presented by Philip G., Novoprotein Scientific

C059: From DNA to Active, Monomeric β1AR Receptor in <72 Hours, Presented by Srishti G., Nuclera

C060: Integrated Drug Discovery: Multiple Hit Identification Campaigns and Successful Hit-to-Lead Progression of Novel Inhibitors of Juno/Izumo1 Interaction, Presented by Charlotte K., Nuvisan

C061: o2h's Integrated Phenotypic and Target-Based In Vitro Biology Platforms for Smarter, Faster Drug Discovery, Presented by Gayathri S., o2h

C062: Development of OmniUltra™: A Transgenic Chicken System for the Generation of Ultralong CDRH3 Antibodies, Mini-Proteins, and Structured Peptides, Presented by Brian M., OmniAb

C063: Pharmacological Evaluation of Bioconjugated Trastuzumab Using the AbYlink™ Regio-Selective Conjugation Technology in Gastric Cancer Expressing HER2+, Presented by Maral M., Oncodesign Services

C064: A Medium-Throughput Organelle-Based Toolbox to Interrogate Diverse Drug Targets Across Therapeutic Areas, Presented by Hugo C., ORIA Bioscience

C065: pH-Dependent FcRn Binding and Release Assay in a Microplate: A New Method for Screening Fc Interactions of mAbs, Bispecifics and Fc Engineered Antibodies, Presented by Sebastian G., PAIA Biotech GmbH

C066: Extensive Developability Profiling of a Diverse mAb Panel – From Biophysical Insight to PK Prediction, Presented by Kristina L., PAIA Biotech GmbH

C067: mRNA Display: Revolutionizing Drug Discovery, Presented by Yongjin G., PeptiFinder Biotech, Inc.

C068: Bioequivalence and Dosimetry Estimates of GD2-Targeting Dinutuximab-Beta Labelled with Indium-111, Lutetium-177, and Actinium-225, Presented by Sean C., Perceptive, Inc.

C069: A New Platform for Imaging Alpha Emitting Radiopharmaceuticals in Pre Clinical Cancer Models, Presented by Gengyang Y., Perceptive, Inc.

C070: ZoeStar™: A Building Block-Centered AI-Driven Drug Discovery Platform Integrating Chemical Space Exploration, Molecular Generation, and Lead Optimization, Presented by Jun L., PharmaBlock Sciences

C071: Driving Molecular Alignment with QM-Derived Descriptors to Analyse Kinase Selectivity Profiles, Presented by Matthew M., Pharmacelera

C072: Optimization and Expansion of Fragment-Based Screening Libraries Through Reaction-Aware Virtual Design, Presented by Matthew M., Pharmacelera

C073: Thorough Antibody Validation for Robust Spatial Biology Data, Presented by Richard W., Pharmagene Discovery Services

C074: Exploring Functional Interactions In Situ Using a Combined Multiomic Approach, Presented by Natalie W., Pharmagene Discovery Services

C075: Direct-to-Biology (D2B) Approach for Accelerated Targeted Protein Degrader Discovery, Presented by Chris W., Pharmaron

C076: Proteomic Profiling Uncovers Synergistic Anti-Leukemic Efficacy of Lasmotinib and Menin Inhibitors in AML, Presented by Jinsun K., Pharos iBio Co., Ltd.

C077: A Fully Transparent and Automatable Focal Graph AI Platform for Biomarker and New Target Discovery Using Diverse Multi-Omics and Chemical Structure Data, Presented by Jedidiah G., Plex Research

C078: BRETSA: An Ultra-Sensitive, Broadly-Applicable BRET Method to Measure Target Engagement and Cellular Cooperativity Using Protein Denaturation, Presented by Kristin H., Promega Corporation

C079: Lumit® Cell Proliferation Assay (Human Ki-67) with Optimized Performance for Screening Applications, Presented by Amy L., Promega Corporation

C080: Real-Time Monitoring of Targeted Protein Degradation in Living Cells: Enabling Live-Cell Kinetic Analysis at Every Step, Presented by Tian Y., Promega Corporation

C081: Lumit-Based Profiling of Degrader Dynamics Reveals Signaling-Dependent, Cell Context-Specific Sensitivity to Degraders, Presented by Hicham Z., Promega Corporation

C082: From Undruggable to Actionable: Transcriptomic Discovery of Small-Molecule Modulators of Oncogenic Transcription Factors, Presented by Arianna S., QUANTRO Therapeutics GmbH

C083: Evaluation of HUNK Inhibition by an FDA-Approved Drug as Potential Therapeutic Strategy for Aggressive Breast Cancer Subtypes, Presented by Safnas AS., Reaction Biology Corporation

C084: A Comprehensive LinkLight Platform for GPCR Mechanistic Profiling to Support Cancer Drug Discovery, Presented by Kelli C., Reaction Biology Corporation

C085: Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR, Presented by Johan E., RG Discovery AB, part of Pelago Bioscience

C086: Stabilizing Challenging Membrane Proteins for Small-Molecule Drug Discovery with the Salipro Technology, Presented by Peter J., Salipro Biotech AB

C087: A Rapid and Accurate Workflow to Classify Atropisomerism in Drug-Like Molecules, Presented by Philip G., Schrödinger, Inc.

C088: Experimental Benchmarking Defines AI Applicability in SLCs, Presented by Naoki T., SEEDSUPPLY, INC.

C089: SpiroQuest: Macrocycle Library, Novel Macrocycle Design and Virtual Library, Presented by Thomas F., SpiroChem AG

C090: Fragment Screening by Spectral Shift to Identify Ligand-Efficient Binders to the VHL-EloC-EloB (VCB) Complex for PROTAC Handle Development, Presented by James F., Sygnature Discovery

C091: The Agile Chemistry Foundry: Connecting Artificial Intelligence with Custom Robotic Synthesis to Accelerate Molecular Discovery, Presented by Nathan C., Synfini, Inc.

C092: Optimizing Medium-Scale Protein Production Using Lynx Automation, Presented by Laurie W. & Nattakan S., Takeda Pharmaceuticals U.S.A., Inc.

C093: Development of a Robust Serum-Free Directed Differentiation Protocol for Functional hiPSC-Derived Endothelial Cells, Presented by Peter U., Trailhead Biosystems

C094: In Vitro Reconstituted Ubiquitylation Assays for Mechanistic Studies of Cullin-RING Ligases, Presented by Bradley B., Trilogie Bioscience

C095: In Vitro Reconstituted Ubiquitylation Assays for Mechanistic Studies of E3 Ligases, Presented by Bryan D., Trilogie Bioscience

C096: Assessing Plate Consistency of LumiPore-Based Intracellular Delivery in Drug Screening, Presented by Jan V., Trince

C097: High-Throughput Protein Stability Screens with Aunty, Presented by Andre M., Unchained Labs

C098: Antibody Discovery for Complex Membrane Antigens, Presented by Ernest S., Vaccinex, Inc.

C099: Initial Efforts to Discover Novel PRMT6 Inhibitors via AI-Driven Design and Synthesis, Presented by Peter G., Variational AI

C100: Innovative Assays for Small Molecule Drug Screening, Presented by Zack Z., Vazyme Biotech Co., Ltd.

C101: DELs in Cells - Discovery of Small-Molecule Modulators of the Oncogenic Transcription Factor SOX2, Presented by Leif L., Vipergen ApS

C102: Synthetic-Lethality Screening with PARP1 Inhibition and Novel Non-CRBN Based Degrader Identification via High-Throughput Screen and Target Deconvolution by Proximity Labeling, Presented by Xia D., WuXi AppTec

C103: Spectral Shift Technology as Powerful Tool for Versatile Assay Applications in High-Throughput, Presented by Moran JW., WuXi AppTec

C104: An Integrated Service Platform to Support the Discovery of Dual-Targeting Oligonucleotide Drugs to Treat Elevated ASCVD Risk in Diabetes, Presented by Jack W., WuXi AppTec

C105: Beyond Conventional HTS: Complementary Strategies for Discovering Modulators of Challenging Transcription Factors, Presented by Yunjin W., WuXi AppTec

C106: Advancing AOC Development Through Linker Design and WuXiDARx™ DAR 1 Conjugation, Presented by Rachana O., WuXi XDC Co., Ltd.

C107: ReadiDEL: An Off-the Shelf DEL Platform that Accelerates Hit Discovery to Clinical Candidates, Presented by Ying Z., X-Chem, Inc.

C108: Next-Generation TCR-Like Antibodies with Improved Specificity Profiles, Presented by Yemi O., YUMAB GmbH

C109: Biophysics-Driven Molecular Glue Discovery, Presented by Gregg S., ZoBio

C110: Agentic AI for Autonomous Discovery, Presented by Tilly S., XtalPi, Inc.

ADDITIONAL VIRTUAL POSTERS

V1: Identification of Rapid-Acting, Orally Bioavailable Antidepressants via Selective Activation of TrkB Signaling, Presented by Wei C., Chengdu Di'ao Pharmaceutical Co., Ltd.

V2: A Roadmap for Systematic Discovery of Novel Binding Pockets via Macromolecular Crystallography and QMMM, Presented by Jose BN., Diamond Light Source Ltd.